Page 1 of 12
This document provides a short summary of this study for a general audience. You
can find more information in the scientific summaries of the study. Links to those
summaries are provided at the end of this document.
Study names
Short Title: A study to learn about the effect of fostemsavir in adults with HIV-1
resistant to multiple antiretroviral medicines.
Full Scientific Title: A multi-arm, phase 3, randomised, placebo-controlled, double-
blind clinical trial to investigate the efficacy and safety of fostemsavir in heavily
treatment-experienced subjects infected with multi-drug resistant HIV-1
(BRIGHTE study).
ViiV Healthcare Study Number: 205888
Who sponsored this study?
ViiV Healthcare (the study was originally sponsored by Bristol Myers Squibb)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When was this study done?
The study started in February 2015. Enrolment was closed, but the study was
ongoing when this summary was finalised. The results presented in this summary
include data collected up to August 2018.
What was the main objective of this study?
Human immunodeficiency virus type 1 (HIV-1) damages the body’s defence system
(immune system). This weakens the body’s ability to fight infections and increases
the risk of developing diseases.
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of ViiV Healthcare as the source of the data be
given. ViiV Healthcare/GSK disclaims liability for all uses of the data by users of this Document, to the
fullest extent permitted by applicable law. No trademark, patent, or regulatory/data exclusivity rights
held by ViiV Healthcare/GSK are waived, licensed or otherwise affected.